Abstract

Transcatheter aortic valve replacement (TAVR) has been developed as a less-invasive approach to address patients at high risk to extreme risk for surgical aortic valve replacement. The CoreValve US trial enrolled patients with symptomatic severe aortic stenosis into 2 separate cohorts: an extreme-risk cohort and a high-risk cohort. The study of transfemoral TAVR using the CoreValve system in extreme-risk patients achieved its primary end point of all-cause mortality or stroke at 1 year. This was achieved with a low stroke rate and low paravalvular leak rate that improved with time. The CoreValve high-risk trial is the only randomized trial of TAVR vs surgical aortic valve replacement to show superior survival of TAVR. This was achieved with a numerically lower rate of major stroke and statistically superior changes in aortic valve function from baseline to 1 year.

Original languageEnglish (US)
Pages (from-to)179-186
Number of pages8
JournalSeminars in Thoracic and Cardiovascular Surgery
Volume26
Issue number3
DOIs
StatePublished - Feb 3 2014

Keywords

  • CoreValve
  • Extreme risk
  • High risk
  • Pivotal study
  • TAVR

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The CoreValve US Pivotal Trial'. Together they form a unique fingerprint.

Cite this